Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065909 | 1.00 | EPHX2 (0.45) | EPHX2MEN1FAAHTP53CYP1A2 | |
| SCHEMBL14597533 | 0.98 | EPHX2 (0.44) | EPHX2MEN1FAAHTP53CYP1A2 | |
| SCHEMBL14597549 | 0.94 | EPHX2 (0.41) | EPHX2MEN1FAAHTP53CYP1A2 | |
| SCHEMBL10065904 | 0.91 | EPHX2 (0.44) | EPHX2MEN1FAAHTP53CYP1A2 | |
| SCHEMBL13679062 | 0.91 | EPHX2 (0.44) | EPHX2MEN1FAAHTP53CYP1A2 | |
| SCHEMBL11321528 | 0.91 | MEN1 (0.42) | MEN1CYP1A2KMT2A | |
| SCHEMBL11313633 | 0.91 | MEN1 (0.42) | MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL5533556 | 0.89 | SPHK1 (0.43) | MEN1CYP1A2KMT2A | |
| SCHEMBL14597551 | 0.88 | EPHX2 (0.42) | EPHX2SLC6A5 | |
| SCHEMBL10007258 | 0.87 | SLC6A5 (0.54) | EPHX2MEN1FAAHTP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9358300-B2 | Transfection reagents | Life Technologies Corporation (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150190522-A1 | TRANSFECTION REAGENTS | LIFE TECHNOLOGIES CORP (US) | 2015-07-09 | — | — | US | disclosed |
| US-8785200-B2 | Transfection reagents | Life Technologies Corporation (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120238747-A1 | TRANSFECTION REAGENTS | Life Technologies Corporation (US) | 2012-09-20 | — | — | US | disclosed |
| US-7601872-B2 | Transfection reagents | Life Technologies Corporation (US) | 2009-10-13 | — | — | US | disclosed |
| US-7479573-B2 | Transfection reagents | INVITROGEN CORPORATION (US) | 2009-01-20 | — | — | US | disclosed |
| US-7173154-B2 | Transfection reagents | INVITROGEN CORP. (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238747-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | EPHX2 3366/4885MEN1 2525/4885FAAH 4748/4885 |
| US-20150190522-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | EPHX2 3270/4885MEN1 2562/4885FAAH 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.